Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with...

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are standard first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.
• Identifying co-occurring genetic alterations may reveal biomarkers for predicting EGFR-TKI treatment efficacy.

Purpose of the Study:

• To investigate the prevalence of concomitant genetic alterations in advanced EGFR-mutant NSCLC patients treated with first-generation TKIs.
• To explore the association between these co-occurring mutations and treatment outcomes.

Main Methods:

• Retrospective analysis of 33 advanced EGFR-mutant NSCLC patients treated with first-generation TKIs.
• Multi-gene panel next-generation sequencing to identify genetic alterations.
• Correlation analysis between genetic alterations and progression-free survival (PFS) and overall survival (OS).

Main Results:

• 78.8% of patients had at least one concomitant genetic alteration.
• TP53 mutations were most frequent (30.3%), followed by CDK4 (24.2%) and CDKN2A copy number variation (CNV) (21.2%).
• FGFR3 mutations and CDKN2A CNV loss were associated with significantly shorter PFS.
• Any concomitant genetic alteration correlated with worse OS.

Conclusions:

• Concurrent genetic mutations are common in advanced EGFR-mutant NSCLC and are unfavorably associated with EGFR-TKI treatment response.
• FGFR3 mutations and CDKN2A CNV loss show potential as predictive biomarkers for treatment outcomes in this patient population.